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Abstract
Evidence from observational studies suggest a positive association between serum 
thyroid-stimulating hormone (TSH) levels and differentiated thyroid carcinoma. However, 
the cause–effect relationship is poorly understood and these studies are susceptible 
to bias and confounding. This study aimed to investigate the causal role of TSH in both 
benign thyroid nodules and thyroid cancer in up to 451,025 UK Biobank participants, 
using a genetic technique, known as Mendelian randomization (MR). Hospital Episode 
Statistics and Cancer Registry databases were used to identify 462 patients with 
differentiated thyroid carcinoma and 2031 patients with benign nodular thyroid disease. 
MR methods using genetic variants associated with serum TSH were used to test causal 
relationships between TSH and the two disease outcomes. Mendelian randomization 
provided evidence of a causal link between TSH and both thyroid cancer and benign 
nodular thyroid disease. Two-sample MR suggested that a 1 s.d. higher genetically 
instrumented TSH (approximately 0.8 mIU/L) resulted in 4.96-fold higher odds of benign 
nodular disease (95% CI 2.46–9.99) and 2.00-fold higher odds of thyroid cancer (95% CI 
1.09–3.70). Our results thus support a causal role for TSH in both benign nodular thyroid 
disease and thyroid cancer.
Introduction
Thyroid cancer is the most common endocrine 
malignancy, with recent years seeing a significant increase 
in incidence (Kitahara & Sosa 2016). The majority 
of patients present with a thyroid nodule; however, 
nodules are common with a prevalence of up to 34% 
on ultrasound (Moon et  al. 2018) and only 5–10% of 
nodules are malignant (Hegedüs 2004, Perros et al. 2014). 
Following clinical assessment, ultrasonography and 
cytological analysis of fine-needle aspiration biopsy the 
true nature of the nodule remains indeterminate in up 
to 25% of cases and up to one-third of surgically excised 
nodules are in fact benign (Bongiovanni et  al. 2012). 
There is, therefore, a need for better stratification of 
thyroid nodules according to risk of malignancy, and 
while recent years have seen the development of genomic 
tests to aid diagnosis (Nikiforov & Baloch 2019), these are 
yet to be widely used in clinical practice.
In addition to ultrasonography and fine-needle 
aspiration biopsy, thyroid function tests including 
serum thyroid-stimulating hormone (TSH) level are 
recommended in the investigation of a thyroid nodule 
(Perros et al. 2014, Haugen et al. 2016). The role of serum 
TSH testing is primarily to identify hyperthyroidism 
caused by a toxic nodule; however, several authors have 
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reported an association between raised serum TSH and 
thyroid cancer (Boelaert et  al. 2006, Fighera et  al. 2015, 
Zafón et al. 2015, Golbert et al. 2017) as well as a correlation 
between serum TSH and aggressiveness of thyroid cancer 
(Haymart et al. 2008, 2009, McLeod et al. 2014).
Despite the strong observational basis for an 
association between serum TSH and thyroid cancer 
in patients with thyroid nodules, there is significant 
difficulty in establishing a causal link due to the difficulty 
in adequately adjusting for confounding factors, such 
as iodine deficiency, autoimmune thyroid disease and 
cigarette smoking (Singh et  al. 1999, Zimmermann & 
Galetti 2015, Cho et  al. 2018) and the possibility of 
reverse causality. This difficulty can be overcome by using 
genetic epidemiological techniques such as Mendelian 
randomization (MR), which relies upon the fact that 
genetic variants predisposing to a certain trait are inherited 
randomly at conception and are not affected by many 
confounders acting upon observational associations. The 
aim of this study was to test the hypothesis that elevated 
serum TSH has a causal role in the development of benign 
thyroid nodules and differentiated thyroid cancer, using 
genetic data from 451,025 participants in the UK Biobank.
Methods
Participants
We used data from the UK Biobank, a longitudinal study 
of 500,000 participants aged between 40 and 69 years 
who were recruited between 2006 and 2010 (Collins 
2012, Sudlow et al. 2015). After giving informed written 
consent, participants gave blood, urine and saliva samples 
for biomarker measurement and genotyping, as well 
as having anthropometric measurements at the time of 
enrolment. In addition, patients filled out demographic 
and health questionnaires and consented to record 
linkage with national cancer and death registries as 
well as the Hospital Episode Statistics (HES) database. 
UK Biobank has received ethics approval from the 
National Health Service National Research Ethics Service 
(ref 11/NW/0382).
Genotyping was performed on DNA extracted from 
whole blood samples by Affymetrix, using two specially 
designed SNP arrays with over 95% content overlap. 
The UKBiobank Axiom array® was used for ~450,000 
participants and the UK BiLEVE Axiom array® for 
50,000 participants (Welsh et al. 2017). Extensive central 
quality control was carried out by the UK Biobank 
(Bycroft et  al. 2018). Genotyping data were subjected 
to multilevel quality control, with exclusion of sex 
mismatches (genetic sex different from reported sex), 
duplicated individuals and outliers of heterozygosity. 
After these exclusions, as well as those individuals who 
have subsequently withdrawn from the UK Biobank 
Study, 451,025 individuals of White European descent 
were identified using principal components computed 
from the 1000 Genomes Project. The KING kinship matrix 
was then used to remove related individuals up to three 
degrees of separation and identify a subset of 379,708 
unrelated individuals for sensitivity analysis. Ancestral 
principal components were generated among this group 
of individuals.
Exposure and outcome measures
We identified two outcome groups of interest within 
the UK Biobank: those with a diagnosis of differentiated 
thyroid cancer and those with a diagnosis of benign 
nodular thyroid disease. In order avoid reporting bias, 
we discounted self-reported diagnoses in the health 
questionnaire and used Cancer Registry and HES data only. 
Thyroid cancer cases were identified by the ICD-10 code 
‘C73’. Histology codes were then used to exclude patients 
with medullary thyroid carcinoma, anaplastic carcinoma, 
thyroid lymphoma and unclassified subtypes, leaving 
only patients with differentiated thyroid carcinoma. This 
resulted in 462 cases. Patients with a diagnosis of benign 
nodular thyroid disease were identified by the ICD-10 
code ‘D34‘. Patients diagnosed with both nodular thyroid 
disease and thyroid cancer were excluded to avoid bias 
caused by misdiagnosis (n = 147). This left 2031 cases in 
total. Control groups with no previous diagnosis of cancer 
and no previous diagnosis of benign thyroid disease 
were also created, numbering 391,458 and 448,532, 
respectively.
The exposure of interest in this study was a genetic 
predisposition to higher TSH levels. In order to quantify 
this, we utilized 20 SNPs associated with TSH levels at 
genome wide significance (P-value threshold of 5 × 10−8) 
in a meta-analysis of 26,420 individuals of European 
ancestry across 18 cohorts (Porcu et  al. 2013) (Table 1). 
Linkage disequilibrium (LD) was calculated using the 
LDlink SNPClip application, with an R2 threshold of 0.1 
and a minor allele frequency (MAF) threshold of 0.01 
(Machiela & Chanock 2015). No SNPs were removed due 
to LD. The 20 SNPs have been reported to account for 
5.64% of variance in serum TSH levels (Porcu et al. 2013). 
The effect of the included SNPs on thyroid-specific gene 
https://doi.org/10.1530/ERC-20-0067
https://erc.bioscientifica.com © 2020 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/24/2020 09:03:48AM
via free access
553J M Fussey et al. TSH and thyroid cancer: 
genetic epidemiology
27:10Endocrine-Related 
Cancer
expression was investigated using the Genotype-Tissue 
Expression Consortium tool (www.gtexportal.org) and is 
shown in Table 1.
Data analysis
In order to identify the causal effect of TSH on thyroid 
cancer and benign nodular thyroid disease, we performed 
two-sample Mendelian randomization (MR) (Bowden et al. 
2016a) using the 20 known genetic variants associated 
with TSH (Porcu et  al. 2013). We corrected for inter-
relatedness by performing a GWAS of the thyroid cancer 
and benign nodular thyroid disease variables using a linear 
mixed model in the BOLT-LMM software (Loh et al. 2015). 
The 20 known TSH variants were then extracted from these 
GWAS analyses for use in the two-sample MR. The SNP-TSH 
association was taken from the primary GWAS by Porcu 
et al., while the SNP-outcome association was taken from the 
BOLT-LMM GWAS of our UK Biobank outcome traits. 
Using the median s.d. (0.8 mIU/L) from the meta-analysis 
of studies used to identify genetic variants associated with 
TSH (Porcu et  al. 2013), the coefficients from the two-
sample MR were adjusted to approximate the odds ratios 
per unit increase in TSH.
MR relies upon the fact that the instrumental 
variable being used is associated with the risk factor of 
interest, that the instrumental variable is not subject 
to the confounding factors acting upon the association 
between the risk factor and outcome of interest and that 
the instrumental variable is associated with the outcome 
of interest only via its effect on the risk factor of interest. 
Figure 1 illustrates the principles of MR.
Three different methods of two-sample MR were 
performed. First, inverse variant weighted (IVW) 
instrumental variable analysis. IVW assumes that all 
Table 1 TSH SNPs, their effect sizes on TSH (modified from Porcu et al. 2013) and their effect on thyroid-specific gene 
expression.
Chromosome Position Effect/other allele SNP Effect size s.e. Thyroid-specific gene expression 
5 76566105 A/G rs6885099 −0.141 0.009 No
6 165966473 C/G rs753760 0.100 0.010 Yes
1 19713761 A/G rs10799824 −0.113 0.012 Yes
16 78306854 T/C rs3813582 0.082 0.010 Yes
6 43919740 T/C rs9472138 −0.079 0.010 Yes
6 44012758 T/C rs11755845 −0.065 0.010 Yes
4 149888956 T/C rs10032216 0.087 0.011 Yes
2 217333768 A/G rs13015993 0.078 0.010 Yes
17 67639131 T/C rs9915657 −0.064 0.009 Yes
1 61393084 A/G rs334699 −0.141 0.021 No
15 47533656 A/T rs10519227 −0.072 0.011 Yes
11 45184143 T/C rs17723470 −0.065 0.010 Yes
15 86920108 A/G rs17776563 −0.060 0.010 Yes
19 7174848 T/G rs4804416 −0.057 0.009 No
9 135129086 A/C rs657152 0.058 0.009 No
14 92665344 A/C rs11624776 −0.064 0.011 Yes
8 32535816 A/G rs7825175 −0.066 0.001 Yes
14 35643769 T/C rs1537424 −0.052 0.009 Yes
6 148562985 T/C rs9497965 0.051 0.009 No
9 4257209 A/G rs1571583 0.057 0.010 No
Positions given are in build 36. Tissue-specific expression information from the Genotype-Tissue Expression Consortium (www.gtexportal.org).
Figure 1
If a risk factor, for example, high TSH truly causes an outcome, for 
example, thyroid cancer, then the genetic variants for the risk factor 
should also be associated with the outcome. Unlike the observed risk 
factor, the genetic variants are not susceptible to confounding by other 
risk factors or reverse causation (dashed lines) as they are assigned at 
conception. Horizontal pleiotropy (dotted line), whereby the variants of 
interest also affect the outcome via their association with another trait is 
a possible limitation of MR.
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genetic instruments are valid and is therefore susceptible 
to horizontal pleiotropy (variants affecting the outcome 
via a route other than the risk factor of interest). To reduce 
this potential source of bias, we also used the MR-Egger 
and Median MR techniques (Bowden et al. 2016a,b) which 
are more robust to pleiotropy. In MR-Egger analysis, the 
intercept is unconstrained to allow a weighted regression, 
thus removing the assumption that all variants are valid 
instrumental variables. This reduces the possibility of 
variants having a stronger effect on the outcome than the 
exposure itself (actual TSH levels). Median-MR is also more 
resistant to pleiotropy, as it uses the median instrumental 
variable from all included variants and allows for up to 
50% of the variants to be invalid.
In order to allow for sensitivity analyses, the effect 
sizes of the 20 included TSH-associated SNPs were used to 
produce a genetic risk score (GRS) for TSH in the smaller 
subset of 379,708 unrelated UK Biobank participants. This 
group contained 425 cases of differentiated thyroid cancer 
and 1812 cases of benign nodular thyroid disease. The 
association between these GRSs and the outcome traits 
of benign nodular thyroid disease and thyroid cancer 
was then tested using a logistic regression model with 
adjustment for age, sex, ancestral principal component 
and recruitment center. Robust s.e. were used to allow 
for uncertainty in the estimate. In addition, the 379,708 
unrelated participants were divided into quartiles based 
on their GRS for TSH, and logistic regression analysis 
was used to test the association between GRS quartile 
and both disease outcomes. Finally, sensitivity analysis 
was performed to account for patients with a diagnosis 
of either hyper- or hypothyroidism as identified in the 
self-reported health questionnaire or the Hospital Episode 
Statistics data. A post hoc power calculation using a 
Mendelian randomization power calculator (Brion et  al. 
2013) confirmed the power of the study to detect a true 
odds ratio of 4.96 for the binary outcome of benign 
nodular thyroid disease per 1 s.d. increase in genetically 
determined TSH (Power = 1.00; α = 0.05; non-centrality 
parameter = 850.45; F statistic = 26959.26); and a true odds 
ratio of 2.00 for the binary outcome of thyroid cancer per 
1 s.d. increase in genetically determined TSH (Power 1.00; 
α = 0.05; non-centrality parameter = 113.44; F statistic 
26959.26).
Results
Table 2 displays basic information on the unrelated 
subgroup of participants and controls. Participants with 
a diagnosis of benign nodular thyroid disease were more 
likely than controls to be female, have a higher BMI and 
have co-existent type two diabetes mellitus (T2DM), 
hyper- or hypothyroidism. Those with a diagnosis of 
thyroid cancer were also more likely than controls 
to be female, and marginally more likely to be obese, 
Table 2 Summary of demographic characteristics of participants.
Characteristics
Benign nodular 
thyroid disease Controls P-value
 
Thyroid cancer 
Cancer-free 
controls P-value
n 1812 377,896 425 310,176
Female sex 1492 (82.34) 203,244 (53.78) <1 × 10−15 316 (74.35) 165,537 (53.37) 5.6 × 10−17
Mean age at recruitment 
(s.d.), years
58.92 (7.39) 57.23 (8.01) <1 × 10−15 57.72 (7.29) 56.54 (8.04) 0.0022
Smoking status:
 Never 976 (53.86) 203,242 (53.78) 0.04 233 (54.82) 169,785 (54.74) 0.40
 Former 649 (35.82) 133,744 (35.40) 152 (35.76) 107,027 (34.51)
 Current 166 (9.16) 35,774 (9.47) 32 (7.53) 29,261 (9.43)
 Missing 21 (1.16) 5136 (1.36) 8 (1.88) 4103 (1.32)
 Mean townsend 
deprivation index (s.d.)
−1.16 (3.09) −1.48 (2.99) 4.8 × 10−8 −1.63 (2.94) −1.45 (2.99) 0.42
 Mean units of  
alcohol (s.d.)
0.20 (1.07) 0.57 (1.04) 2.5 × 10−6 0.37 (1.00) 0.57 (1.04) 0.48
 Mean BMI (s.d.), kg/m2 27.96 (5.23) 27.38 (4.78) 4.1 × 10−12 27.55 (5.34) 27.38 (4.77) 0.16
 Obese: BMI  
30–40 kg/m2
471 (25.99) 83,503 (22.10) 1.6 × 10−9 111 (26.12) 68,563 (22.10) 0.068
 Type 2 diabetes 70 (3.86) 11,996 (3.17) 0.0037 16 (3.76) 9290 (3.0) 0.16
 Hypothyroidism 182 (10.04) 18,600 (4.92) 4.8 × 10−9 28 (6.59) 15,238 (4.91) 0.12
 Hyperthyroidism 59 (3.26) 2897 (0.77) 1.6 × 10−4 7 (1.65) 2377 (0.77) 0.35
Table represents data after exclusion of related individuals due to the difficulty in adjusting observational analyses for relatedness. Values stated are 
numbers (percentages), unless otherwise stated. P-values calculated using logistic regression adjusted for age and sex.
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with a higher proportion than controls having co-existent 
hyper- or hypothyroidism.
Two-sample MR
Two-sample MR provided evidence that higher TSH 
caused both benign nodular thyroid disease and thyroid 
cancer. A 1 s.d. (approximately 0.8 mIU/L) higher 
genetically instrumented TSH level was associated 
with 4.96 higher odds of benign nodular thyroid (95% 
CI 2.46–9.99) and 2.00 higher odds of thyroid cancer 
(95% CI 1.09–3.70; Fig. 2 and Table 2). This approximates 
to 7.39 times higher odds of benign nodular thyroid 
disease (95% CI 3.67–14.90) and 2.39 times higher odds 
of thyroid cancer (95% CI 1.29–4.40) per 1 mIU/L higher 
TSH. The more pleiotropy-resistant two-sample analyses 
were directionally consistent and MR-Egger provided 
no evidence of horizontal pleiotropy for either outcome 
trait (Table 3).
Sensitivity analyses
The GRS for TSH was associated with both benign nodular 
thyroid disease and thyroid cancer in the subgroup of 
unrelated participants. Using logistic regression adjusted 
for age, sex, ancestral principal component and assessment 
center with the GRS for TSH as the dependent variable, 
we found a positive association with benign nodular 
Figure 2
Forest plot showing two sample MR (instrumental variable analysis) 
associations between genetically instrumented TSH and thyroid cancer 
and benign nodular thyroid disease. Odds ratios of outcome per s.d. 
higher genetically instrumented TSH and 95% CIs are shown. Ta
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thyroid disease, with each weighted allele increase in the 
TSH GRS resulting in 1.11-fold higher odds of benign 
nodular thyroid disease (95% CI 1.10–1.13; Fig. 3). 
Similarly, there was a positive association with thyroid 
cancer, with an odds ratio of 1.05 (95% CI 1.02–1.09; 
Fig. 3). Furthermore, individuals in the top 25% of the 
TSH GRS were at 1.34 higher odds of thyroid cancer 
(95% CI 1.14–1.50; Fig. 4) and 2.23 higher odds of benign 
nodular thyroid disease (95% CI 1.89–2.63) than those 
in the bottom 25%. Results of the sensitivity analysis 
after excluding participants with hypothyroidism or 
hyperthyroidism, which did not affect the associations, 
are shown in Table 4. Finally, the analysis using TSH GRS 
in the unrelated subgroup was repeated separately in male 
and female participants (Table 5) with the associations 
with both benign nodular disease and thyroid cancer 
remaining stable in females, but the association with 
thyroid cancer weakening in males.
Discussion
Principal findings
This study investigated the causal relationship between 
serum TSH levels and thyroid cancer risk and benign 
nodular thyroid disease risk. Our results reveal a significant 
association between genetic variants predicting higher 
serum TSH and both diagnoses. Furthermore, these results 
were consistent when using different approaches.
The first study to identify an association between 
serum TSH levels and risk of thyroid cancer was published 
by Boelaert et  al. (2006) and since then many authors 
have reported similar findings, with two meta-analyses 
reporting positive associations (McLeod et  al. 2012, 
Zheng et  al. 2016). However, the majority of included 
studies were retrospective, resulting in bias and difficulty 
in adjusting for all confounders. There is also some 
controversy on the subject, with the EPIC case-control 
study reporting a negative association among its 357 cases 
and 767 matched controls (Rinaldi et al. 2014), and a more 
recent case-control study on papillary thyroid carcinoma 
identifying a positive association in men and a negative 
association in women (Huang et al. 2017). Furthermore, 
differentiated thyroid cancer has been reported even in 
patients with completely suppressed TSH levels (Satta 
et al. 1993), although the authors note that tumors may 
have arisen prior to development of thyrotoxicosis. 
Here, we demonstrated stronger evidence of a role for 
TSH in thyroid cancer in women than in men. However, 
these analyses were limited by the low numbers of male 
participants with thyroid cancer in the UK Biobank study. 
When testing the role of TSH on benign thyroid nodules, 
results were similar in men and women.
The widely proposed mechanism explaining the 
positive association between serum TSH levels and both 
benign thyroid nodules and thyroid cancer reported by 
Figure 3
Forest plot showing associations between genetically instrumented TSH and 
thyroid cancer and benign nodular thyroid disease. Odds ratios of outcome 
per s.d. higher genetically instrumented TSH and 95% CIs are shown.
Figure 4
Forest plot showing associations between quartiles for TSH genetic  
risk and thyroid cancer and benign nodular thyroid disease. Odds ratios 
and 95% CIs are shown for each quartile as compared to those in the 
lowest quartile.
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most studies is the thyrotropic effect of TSH. TSH is known 
to induce proliferation of thyrocytes and both benign 
and malignant thyroid tumors have long been known to 
express TSH receptors (Ichikawa et al. 1976). Furthermore, 
suppression of TSH is a well-established adjunct to the 
management of differentiated thyroid carcinoma (Perros 
et al. 2014) and has in the past been used in the treatment 
of benign nodular thyroid disease although has now 
largely been abandoned in this setting due to long-term 
adverse effects (Wémeau et  al. 2002). Animal studies 
have demonstrated a convincing role for TSH in thyroid 
tumorigenesis (Lu et  al. 2010) however the cause-effect 
relationship between high TSH and thyroid cancer in 
humans is unclear due to the difficulty in accounting for 
known and unknown confounders.
The aim of this study was to test the hypothesis that 
TSH has a causal role in the development of thyroid cancer, 
using genetic techniques. Our findings while positive, 
are not sufficient to change clinical practice. They do, 
however, add to the debate on the topic and represent 
evidence using a novel technique that higher TSH does 
increase the risk of both benign nodular thyroid disease 
and thyroid cancer. It is vital that this causal relationship 
is understood when considering previously published 
observational and clinical studies on the link between 
TSH and thyroid cancer. Furthermore, our findings 
help pave the way for future research on the ability of 
genetic instruments to distinguish between benign and 
malignant thyroid nodules, with the advantage that 
they are not confounded by environmental factors. This 
information may eventually be used along with other 
genetic instruments to formulate pre-diagnostic screening 
or stratification tools to aid clinical decision making in 
patients with thyroid nodules.
Strengths and limitations
The advantage of the present study is the ability to 
limit the effect of environmental confounders by using 
genetic predictors of TSH levels, which are fixed at 
conception. This is the first study using Mendelian 
randomization to investigate the link between TSH 
levels and benign nodular thyroid disease and thyroid 
cancer. The main limitation of the study is the lack of an 
observational measure of TSH in the UK Biobank cohort. 
This problem is partially overcome by using data from 
large genome wide association studies to confirm robust 
associations between the TSH SNPs we used and TSH 
levels in European subjects; however, the UK Biobank 
participants are inevitably not completely comparable to 
those cohorts. Secondly, the power of our MR analyses 
is somewhat limited by the small number (462) of 
thyroid cancers amongst the UK Biobank participants. 
Finally, the UK Biobank is not representative of the wider 
population, including only UK residents aged between 40 
and 69 at enrolment. There is some evidence of healthy 
volunteer bias within the UK Biobank, with lower rates of 
cancer incidence than the age and sex matched general 
population (Fry et al. 2017).
Conclusions
Using MR, we have demonstrated a causal role for TSH 
in both benign nodular thyroid disease and differentiated 
thyroid cancer. This supports the associations reported by 
many observational studies. Further research is required 
to test the applicability of these findings to the wider 
population and investigate their clinical applicability in 
patients with thyroid nodules.
Table 4 Results of sensitivity analysis for both thyroid cancer and benign nodular thyroid disease after exclusion of participants 
with co-existing diagnoses of hypothyroidism or hyperthyroidism.
 
Analysis
 
Exposure
OR thyroid 
cancer 
 
n = cases (controls)
 
95% CI
OR Benign nodular 
thyroid disease 
 
n = cases (controls)
 
95% CI
Primary analysis TSH 1.05 425 (310,176) 1.02–1.09 1.11 1812 (377,896) 1.10–1.13
Sensitivity analysis TSH 1.05 423 (309,526) 1.02–1.09 1.13 1803 (377,110) 1.11–1.14
Table 5 Results of sensitivity analysis for both thyroid cancer and benign nodular thyroid disease according to sex.
Analysis Exposure
OR thyroid 
cancer n = cases (controls) 95% CI
OR Benign 
nodular thyroid 
disease n = cases (controls) 95% CI
Primary analysis TSH 1.05 462 (391,458) 1.02–1.09 1.11 1812 (377,896) 1.10–1.13
Male sex TSH 1.01 109 (144,639) 0.94–1.08 1.12 320 (174,652) 1.08–1.15
Female sex TSH 1.07 316 (165,537) 1.03–1.11 1.13 1492 (203,244) 1.11–1.15
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